Cambridge Investment Research Advisors, Inc. Viking Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 29,721 shares of VKTX stock, worth $704,982. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,721
Previous 13,419
121.48%
Holding current value
$704,982
Previous $540,000
32.96%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding VKTX
# of Institutions
466Shares Held
65.7MCall Options Held
5.8MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$241 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$143 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$117 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$61.5 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$51.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $1.82B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...